Pharmacosmos picks up G1 Therapeutics, FDA-approved drug Cosela in merger worth $405M
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics Fails Late-Stage Breast Cancer Trial
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics announced that it will be continuing its Phase III breast cancer trial for its drug Cosela following an interim analysis, pushing back a data readout and sending its stock $GTHX down nearly 40%.
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.